Insulet (PODD) Cost of Revenue (2010 - 2026)

Insulet has reported Cost of Revenue for 17 years, with the latest figure at $232.7 million in Q1 2026.

• For the quarter ending Q1 2026, Cost of Revenue rose 45.53% year-over-year to $232.7 million; the trailing twelve-month figure through Mar 2026 stood at $841.0 million (up 29.21% YoY), and the FY2025 full-year result was $768.2 million, up 22.74% from the prior year.
• Cost of Revenue for Q1 2026 stood at $232.7 million, up from $215.2 million in the prior quarter.
• The five-year high for Cost of Revenue was $232.7 million in Q1 2026, with the low at $85.7 million in Q1 2022.
• Historically, Cost of Revenue has averaged $156.7 million across 5 years, with a median of $152.5 million in 2022.
• Annual changes were most pronounced in 2022 — Cost of Revenue surged 6250.0% — and 2023, when it dropped 8.59%.
• Insulet's Cost of Revenue stood at $152.4 million in 2022, then declined by 2.49% to $148.6 million in 2023, then gained by 12.11% to $166.6 million in 2024, then advanced by 29.17% to $215.2 million in 2025, then rose by 8.13% to $232.7 million in 2026.
• The last three Cost of Revenue figures came in at $232.7 million (Q1 2026), $215.2 million (Q4 2025), and $196.2 million (Q3 2025), per Business Quant data.